PriceTargets.com logo

Vicarious Surgical - RBOT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.67
  • Forecasted Upside: 144.29%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.27 As of 04/24/2024 01:00 AM ET
▼ -0.01 (-3.53%)

This chart shows the closing price for RBOT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vicarious Surgical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RBOT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RBOT

Analyst Price Target is $0.67
▲ +144.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Vicarious Surgical in the last 3 months. The average price target is $0.67, with a high forecast of $1.00 and a low forecast of $0.40. The average price target represents a 144.29% upside from the last price of $0.27.

This chart shows the closing price for RBOT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Vicarious Surgical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2024Piper SandlerLower TargetNeutral ➝ Neutral$1.50 ➝ $1.00Low
12/4/2023Morgan StanleyInitiated CoverageEqual Weight$0.60Low
11/14/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$9.00 ➝ $0.40Low
11/14/2023BTIG ResearchReiterated RatingBuy ➝ NeutralLow
7/18/2022BTIG ResearchLower TargetBuy$8.00 ➝ $7.00Low
5/10/2022Piper SandlerLower Target$7.00 ➝ $5.00High
3/4/2022Piper SandlerDowngradeOverweight ➝ Neutral$16.00 ➝ $7.00High
1/7/2022Credit Suisse GroupInitiated CoverageOutperform$16.00High
12/7/2021CowenInitiated CoverageOutperform$15.00Low
10/18/2021BTIG ResearchInitiated CoverageBuy$15.00High
10/7/2021Piper SandlerInitiated CoverageOverweight$16.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Vicarious Surgical logo
Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.27
Low: $0.27
High: $0.28

50 Day Range

MA: $0.33
Low: $0.25
High: $0.52

52 Week Range

Now: $0.27
Low: $0.20
High: $2.46

Volume

177,085 shs

Average Volume

630,770 shs

Market Capitalization

$47.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Vicarious Surgical?

The following equities research analysts have issued reports on Vicarious Surgical in the last year: BTIG Research, Canaccord Genuity Group Inc., Morgan Stanley, and Piper Sandler.
View the latest analyst ratings for RBOT.

What is the current price target for Vicarious Surgical?

3 Wall Street analysts have set twelve-month price targets for Vicarious Surgical in the last year. Their average twelve-month price target is $0.67, suggesting a possible upside of 144.3%. Piper Sandler has the highest price target set, predicting RBOT will reach $1.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $0.40 for Vicarious Surgical in the next year.
View the latest price targets for RBOT.

What is the current consensus analyst rating for Vicarious Surgical?

Vicarious Surgical currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RBOT, but not buy more shares or sell existing shares.
View the latest ratings for RBOT.

What other companies compete with Vicarious Surgical?

Other companies that are similar to Vicarious Surgical include Milestone Scientific, ReWalk Robotics, CollPlant Biotechnologies, Nutriband and Envoy Medical. Learn More about companies similar to Vicarious Surgical.

How do I contact Vicarious Surgical's investor relations team?

Vicarious Surgical's physical mailing address is 78 Fourth Avenue Waltham, MA 02451. The company's listed phone number is 617 868 1700 and its investor relations email address is [email protected]. The official website for Vicarious Surgical is www.vicarioussurgical.com. Learn More about contacing Vicarious Surgical investor relations.